Fig. 2

FOXD3-AS1 repressed miR-127-3p expression in NSCLC cells. a Predicted binding sites between FOXD3-AS1 fragments and miR-127-3p. WT = wild type; MUT = mutated. b qRT-PCR determination of miR-127-3p expression in A549/DDP cells with mimic NC, miR mimics, inhibitors NC or miR inhibitors transfection. c, d Dual-luciferase reporter assay analysis of relative luciferase activity of reporter vector containing wild type or mutated FOXD3-AS1 fragment in A549/DDP cells with mimic NC, miR mimics, inhibitors NC or miR inhibitors transfection. e qRT-PCR determination of miR-127-3p expression in A549 cells transfected with pcDNA3.1, pcDNA3.1-FOXD3-AS1 (WT) or pcDNA3.1-FOXD3-AS1 (MUT). f RNA pull-down assay determined the interaction between FOXD3-AS1 and miR-127-3p. g qRT-PCR determination of miR-127-3p expression in A549/DDP cells with si-NC or si-FOXD3-AS1 transfection. h, i CCK-8 assay determination IC50 values (cisplatin) in A549/DDP cells with mimics NC or miR mimics transfection. j, k CCK-8 assay determination of IC50 values (cisplatin) in A549 cells with inhibitors NC or miR inhibitors transfection. l, m CCK-8 assay determination of IC50 values (cisplatin) in A549/DDP cells after being transfected with different oligonucleotides. Mimics NC = negative control for miR-127-3p mimics; miR mimics = miR-127-3p mimics; inhibitors NC = negative control for miR-127-3p inhibitors); miR inhibitors = miR-127-3p inhibitors. N = 3 biological samples, and each sample was assayed in triplicates. Significant differences between groups were shown as *P < 0.05 and **P < 0.01